Were the Alpha Tau Medical (DRTS) CFO’s transactions option exercises or regular share sales?

The transactions were regular share sales, not option exercises. Both entries are classified as non-derivative Ordinary Shares with the code “S,” described as sales in open market or private transactions, and no conversion or exercise prices are listed.

What is the net share impact of the Alpha Tau Medical (DRTS) CFO’s Form 4 transactions?

The net impact is a reduction of 32,500 shares. The transaction summary shows two sales totaling 32,500 shares, with a net buy/sell direction of “net-sell,” reflecting purely dispositional activity during the reported period.

Alpha Tau Medical (DRTS) CFO Levy Raphi sells 32,500 shares in open-market trades

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi sold shares in the company. On June 3, 2026, he completed two open-market sales totaling 32,500 Ordinary Shares of Alpha Tau Medical Ltd. at prices of $10.7571 and $10.9005 per share. These were reported as non-derivative transactions with direct ownership.

Insights

CFO reported routine open-market share sales totaling 32,500 shares.

Alpha Tau Medical Ltd. Chief Financial Officer Levy Raphi executed two non-derivative, open-market sales of Ordinary Shares on June 3, 2026. He sold 15,000 shares at $10.7571 and 17,500 shares at $10.9005, for an aggregate of 32,500 shares.

Both transactions are classified as sales in the open market or private transactions, with direct ownership and no associated derivative exercises. The filing shows no derivative positions in the accompanying summary, suggesting this activity reflects straightforward share disposals rather than option-related activity.

The overall signal depends on how these sales compare to the executive’s total holdings and the company’s share count, which are not fully detailed in this excerpt. Subsequent filings may provide additional context on longer-term trading patterns or changes in his equity exposure.

Insider Trade Summary

Net Seller: 32,500 shares ($352,115)

Net Sell 2 txns

Insider Levy Raphi

Role Chief Financial Officer

Sold 32,500 shs ($352K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	17,500	$10.9005	$191K
Sale	Ordinary Shares	15,000	$10.7571	$161K

Holdings After Transaction: Ordinary Shares — 162,680 shares (Direct, null)

Footnotes (1)

Key Figures

First sale size: 15,000 shares First sale price: $10.7571 per share Second sale size: 17,500 shares +2 more

5 metrics

First sale size 15,000 shares Ordinary Shares sold on June 3, 2026 at $10.7571

First sale price $10.7571 per share Open-market sale of 15,000 Ordinary Shares

Second sale size 17,500 shares Ordinary Shares sold on June 3, 2026 at $10.9005

Second sale price $10.9005 per share Open-market sale of 17,500 Ordinary Shares

Total shares sold 32,500 shares Combined open-market sales on June 3, 2026

Key Terms

Ordinary Shares, non-derivative, open-market sale, Sale in open market or private transaction, +1 more

5 terms

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

non-derivative financial

"transaction_type: "non-derivative""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Sale in open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

direct ownership financial

"ownership_type: "direct""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 02:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Raphi

(Last)

(First)

(Middle)

C/O ALPHA TAU MEDICAL

PO BOX 45044

(Street)

JERUSALEM

9777605

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alpha Tau Medical Ltd. [ DRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/03/2026	06/03/2026	S		17,500	D	$10.9005	162,680	D
Ordinary Shares	06/03/2026	06/03/2026	S		15,000	D	$10.7571	147,680	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	Raphi Levy	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Alpha Tau Medical (DRTS) CFO Levy Raphi report in this Form 4?

Levy Raphi reported selling 32,500 Ordinary Shares of Alpha Tau Medical. The sales occurred in two open-market transactions on June 3, 2026, and were classified as non-derivative, directly owned share disposals by the company’s Chief Financial Officer.

How many Alpha Tau Medical (DRTS) shares did the CFO sell and at what prices?

The CFO sold 32,500 Ordinary Shares of Alpha Tau Medical. He executed one sale of 15,000 shares at $10.7571 and another of 17,500 shares at $10.9005, both reported as open-market or private transactions.

Does the Alpha Tau Medical (DRTS) Form 4 show any derivative positions for the CFO?

The filing’s derivative summary is empty, indicating no derivative transactions were reported. The two sales involve only non-derivative Ordinary Shares, suggesting the reported activity is limited to direct share disposals rather than options or other derivatives.